Our CEO, Go van Dam, and CBO, Ari Aminetzah, will represent TRACER and participate in the one-on-one partnering meetings at the annual Congress of the European Association of Nuclear Medicine.
For you as a drug developer, this is a great chance to explore opportunities for fast-track clinical trials. Fill out the contact form on this page, to schedule your meeting.
We are excited to meet you in Vienna!
Phase 0 data points
We like to share the most important data points on Phase 0 clinical trials. In our meeting we will elaborate on this and there will be time to answer questions regarding clinical trials for your compound.
- Approved method by FDA and EMA
- Up to a 73% higher chance of success in subsequent trials
- First patient in within 6 months
- On- /off-target data in approximately 12 months
- GLP material is sufficient
- Only limited toxicity studies needed
- Skip large animal studies
- Significantly lower investment in comparison to Phase I
Fill out the form on this page to schedule your meeting at the EANM congres or send an e-mail to info@tracercro.com.